Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer
Status:
Recruiting
Trial end date:
2029-05-31
Target enrollment:
Participant gender:
Summary
To determine the recommended phase 2 dose (RP2D) of niraparib and neratinib in combination in
patients with advanced solid tumors during Phase 1. To evaluate clinical benefit (≥4-month
progression-free survival [PFS]) of niraparib and neratinib in patients with
platinum-resistant ovarian cancer in Phase 1b.